Published date: 16 October 2025

This notice was replaced on 16 October 2025

This notice does not contain the most up-to-date information about this procurement. The most recent notice is:

Awarded contract (published 16 October 2025)

Awarded contract - This means that the contract has been awarded to a supplier.


Contract summary

Industry

  • Vaccines - 33651600

Location of contract

E14 4PU

Value of contract

£0

Procurement reference

CF-3193100D0O000000rwimUAA

Published date

16 October 2025

Closing date

4 December 2024

Closing time

1pm

Contract start date

1 December 2025

Contract end date

30 November 2029

Contract type

Supply contract

Procedure type

Negotiated procedure without prior publication (above threshold)

The opportunity was not advertised, because for example only one supplier is capable of delivering the requirement, or due to extreme urgency brought about by unforeseen events.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

Contract for the supply of human papillomavirus vaccine to be used as part of the national immunisation programme. Deliveries will be required for a four year period from December 2025

Value - The contract value is withheld from publication pursuant to regulation 50(6)(b) of the Public Contracts Regulations 2015 (as amended) so as not to prejudice the legitimate commercial interest of the supplier.

More information

Attachments

Award information

Awarded date

10 October 2025

Contract start date

1 December 2025

Contract end date

30 November 2029

Total value of contract

£1

This contract was awarded to 1 supplier.

Merck Sharpe & Dohme (UK) Limited

Address

120 Moorgate, London, EC2M 6UR

Reference

None

Supplier is SME?

No

About the buyer

Contact name

Lynne Nichols

Address

10 South Colonnade
London
E14 4PU
United Kingdom

Email

vmc.vaccines@ukhsa.gov.uk